ScripWith understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com
In VivoFDA product reviews were the lead story for the year, as Class II device designations emerged for large-panel tumor-profiling assays and direct-to-consumer (DTC) genetic health risk assessment (GHRA)
In VivoDevice Transactions Financing by device companies in the third quarter of 2017 totaled $2.38 billion, double Q2's $1.2 billion. ( See Exhibit 1. ) Debt again this quarter made up most of the aggregate